BOSTON, June 22, 2023 /PRNewswire/ -- Haemonetics Corporation (HAE), a global medical technology company focused on delivering innovative solutions to drive better patient outcomes, today announced it ...
Haemonetics Corporation HAE is well-poised for growth in coming quarters backed by strong end-market demand for NexSys PCS system with Persona technology along with the huge potential of Hemostasis ...
We believe that the stock price of Haemonetics (NYSE: HAE), best known for its blood and plasma supplies and services, is undervalued at current levels of $63. HAE stock is down 27% from the levels of ...
Javascript is required for you to be able to read premium content. Please enable it in your browser settings.
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements in this press release may include, without ...
Haemonetics Corporation’s HAE impressive Hospital business recovery is poised to drive growth in the upcoming quarters. The robust uptake of the NexSys PCS system bodes well for its long-term growth.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results